ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P1106 | DOI: 10.1530/endoabs.63.P1106

Analysis of gender-related differences in clinically non-functioning pituitary adenomas

Nerea Aguirre Moreno1, Miguel Sampedro-Nuñez1,2, Ana Ramos Leví1,2, Rogelio Garcia Centeno3, Concepción Blanco Carrera4, Cristina Alvarez Escolá5, Paz de Miguel Novoa6, María Calatayud Gutierrez7, Soledad Librizzi7 & Mónica Marazuela Azpiroz1,2


1Service of Endocrinology, Hospital Universitario de la Princesa, Madrid, Spain; 2Immunology and Molecular Biology Unit, Instituto de Investigación Princesa, Universidad Autónoma de Madrid, Madrid, Spain; 3Service of Endocrinology, Hospital Universitario Gregorio Marañón, Madrid, Spain; 4Service of Endocrinology, Hospital Universitario Principe de Asturias, Madrid, Spain; 5Service of Endocrinology, Hospital Universitario de La Paz, Madrid, Spain; 6Service of Endocrinology, Hospital Universitario Clínico San Carlos, Madrid, Spain; 7Service of Endocrinology, Hospital Universitario 12 de Octubre, Madrid, Spain.


Introduction: Clinically non-functioning pituitary adenomas (NFPA) are heterogeneous group. Some previous research has found that this type of pituitary adenomas may be smaller and have better prognostic in men. The aim of this study is to analyze if there are gender-related differences in NFPA.

Material and methods: Retrospective study of patients with NFPA followed up in regional hospitals (Community of Madrid, Spain). All NFPA had molecular analysis. The collected variables were: age, sex (women were divided according to premenopausal and menopausal status), diagnostic (NFPA were divided according to type of expression, classified as unihormonal, plurihormonal or null cell), initial tumor size, need of reintervention and radiotherapy. Concerning the molecular study we also included prolactin, GH, POMC, betaLH, betaFSH, betaTSH, alpha subunit, somatostatin receptors (SSTR 1–5), dopamine D1, D2 long, D4 and D5 receptor. Statistical analysis was made with SPSS version 22.0.0.0.

Results: 44 patients were included (age at diagnosis 61±14 years). 54.5% were women (17 menopausal women and 7 premenopausal). All of them were macroadenomas. 3 were silent corticotroph adenomas, 21 gonadotropinomas, 10 plurihormonal adenomas, 1 silent TSH adenomas, 2 silent prolactinomas and 10 were null cell. We found that dopamine receptor D1 expression was higher in silent prolactinomas and null cell adenomas, and was very low in gonadotropinomas (P=0.001). There were statistically significant differences in the type of adenoma according to gender and to menopausal and premenopausal status. Adenomas with hormonal expression were more frequent in premenopausal woman. The most frequent adenomas in men were gonadotropinomas and in menopausal women gonadotropinomas, plurihormonal and null cell adenomas. We observed that dopamine receptor D4 expression was higher in women than in men. There was a trend, although it was not statistically significant, in the need for reintervention (7/13 in men vs 3/21 in women; P=0.076). Gonadotropinomas had higher expression of prolactina and dopamine receptor D4 in women. No difference between tumor size and need of radiotherapy was found.

Conclusion: In our cohort, we found difference in the type of NFPA and dopamine receptor D4 expression between men and women. Also, the dopamine receptor D1 expression was higher in silent prolactinomas and null cell adenomas, and very low in gonadotropinomas.